Opportunities and Threats in the BRIC Pharmaceutical Markets: Assessing the Impact of Recent Pricing, Reimbursement, and Market Access Developments

The “BRIC markets”—Brazil, Russia, India, and China—have been the focus of particular attention from the pharmaceutical industry. Decision Resources tracks pricing, reimbursement, and market access developments in each of these markets and assesses the implications for drug manufacturers seeking to expand their scope into these markets. This white paper describes third-quarter developments and their impact on pharma company strategies.

Please fill out the following form to download this FREE white paper:

*First Name:

*Last Name:

*Job Title:

*Company Name:

*Phone Number:

*Email Address:

Please help us understand your areas of interest in Emerging Markets by answering the following optional questions.

Which emerging markets are of particular interest to you?


Which topics related to these markets are of particular interest to you?


Which elements would you most like to see in reports on emerging markets?

 I have read and agree to abide by the Decision Resources Terms of Use and Privacy Policy.

Required field

Decision Resources Group brands include: